Morphothiadine Mesylate
- Generic Name
- Morphothiadine Mesylate
GLS4/RTV and TAF Drug-drug Interaction
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04551261
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04147208
- Locations
- 🇨🇳
Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Beijing YouAn Hospital,Capital Medical University, Beijing, Beijing, China
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03662568
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03638076
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath